Huntsman Cancer Institute at the University of Utah is a nationally recognized research center and treatment hospital in Salt Lake City. We are the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West and serve patients with all types of cancer from Utah, Idaho, Montana, Nevada, and Wyoming. In 2021, we opened the region’s first proton therapy center. We manage the Utah Population Database, the largest genetic database in the world. More genes for inherited cancers have been discovered at our institution than any place in the world, including genes for melanoma and breast, ovarian, colon, head, and neck cancers.
Huntsman Cancer Institute Researchers Find Link Between Folic Acid and Blood Cell Production
December 27th 2023Researchers at Huntsman Cancer Institute at the University of Utah discovered that the level of blood and immune cells in mouse model offspring would fluctuate based on the amount of folic acid consumed by their mothers during pregnancy.
Digital Tools Quadruple Rate of Lifesaving Lung Cancer Screening
December 23rd 2023Researchers at University of Utah Health have designed new digital tools that use relevant information from patient health records to prompt doctors to consider lung cancer screening for high-risk patients and provide personalized guidance on screening.
Triple Combination Therapies in RCC: Clinical Trial Insights
December 19th 2023Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.
Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC
November 28th 2023Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.
New Clinical Trials Test Innovative Ways To Preserve Muscle Mass During Metastatic Prostate Cancer
October 25th 2023The National Cancer Institute awarded investigators at Huntsman Cancer Institute a grant totaling more than $3 million to conduct a clinical trial to see if combining creatine monohydrate supplementation and resistance exercise training helps preserve muscle in people who have metastatic prostate cancer.
Shaping the Future of Cancer Care Through Student Training Health Collaborative
October 20th 2023Huntsman Cancer Institute at the University of Utah and Utah Valley University proudly announce a groundbreaking partnership called the “Huntsman Cancer Institute–Utah Valley University Health Collaborative.”
Dr Agarwal on Future Questions to Address Following the TALAPRO-2 Trial in mCRPC
July 26th 2023Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Agarwal Discusses FDA Approval of Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
Neeraj Agarwal, MD, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC.
FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
July 17th 2023Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.
Dr Agarwal on Advances With PARP Inhibitors in Prostate Cancer
July 10th 2023Neeraj Agarwal, MD, discusses the role of PARP inhibitors in metastatic castration-resistant prostate cancer and the potential evolutions of the metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer treatment paradigms.
Dr Agarwal on the FDA Approval of Talazoparib Plus Enzalutamide in HRR-Mutated mCRPC
July 6th 2023Neeraj Agarwal, MD, discusses the significance of the FDA approval of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
Addressing Health in Areas Characterized by Persistent Poverty
July 6th 2023The Center for Health Outcomes and Population Equity at Huntsman Cancer Institute and the University of Utah, in partnership with the Montana State University Center for American Indian and Rural Health Equity, received a grant for Cancer Control in Persistent Poverty Areas from the National Cancer Institute.